Protein kinases play a predominant regulatory role in nearly every aspect of cell biology and
they can modify the function of a protein in almost every conceivable way. Protein …

The DNA damage response (DDR) is essential for maintaining the genomic integrity of the
cell, and its disruption is one of the hallmarks of cancer. Classically, defects in the DDR have …

Cancer cells that express oncogenic alleles of RAS typically require sustained expression of
the mutant allele for survival, but the molecular basis of this oncogene dependency remains …

Human non–small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently
respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib …

Limitations on the number of unique protein and DNA molecules that can be characterized
microscopically in a single tissue specimen impede advances in understanding the …

Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Abstract Activating B-RAF (V600E)(also known as BRAF) kinase mutations occur in∼ 7% of
human malignancies and∼ 60% of melanomas. Early clinical experience with a novel class …

Populations of tumour cells display remarkable variability in almost every discernable
phenotypic trait, including clinically important phenotypes such as ability to seed metastases …

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-
driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …